Evaluation of Coenzyme Q10 Redox Status as a Biomarker of Oxidative Stress

The article examines the role of ubiquinone as a redox molecule whose functions consist in electron transport in the mitochondrial respiratory chain and regeneration of endogenous antioxidants. Changes in electron redox pathways cause uncontrolled release of reactive oxygen species, which leads to oxidative stress and development of pathologies. The objective of the study was to determine the content of coenzyme Q10 and its redox status in the human body as a biomarker of oxidative stress in various pathologies. This was achieved by assessing and consolidating data on changes in concentrations of the oxidized, reduced ubiquinone forms and total ubiquinone in various pathologies. Total serum ubiquinone was reduced in patients with chronic heart failure (0.68 μmol/L) compared with the control group (0.97 μmol/L). The redox status, expressed as the [ubiquinol]/ [ubiquinone] concentration ratio, decreased in patients with coronary heart disease (0.49 ± 0.34), diabetes (0.26 ± 0.16) compared with the healthy subjects (1.23–1.41). A negative correlation with malonic dialdehyde was observed. The authors analysed the possibility of assessing the efficacy of statin therapy by plasma ubiquinone concentration in patients. Patients with hyperlipidemia who received statins showed a statistically significant reduction in ubiquinol concentration after taking the drug (from 0.81 to 0.46 μg/mL) and the [ubiquinone]/[total ubiquinone] ratio (from 11 to 10 %), which confirms the potential mechanism of statinassociated muscle injury development. Thus, coenzyme Q10 redox status, as well as the concentrations of oxidized, reduced and total ubiquinone can be effective biomarkers of oxidative stress in cardiovascular diseases, diabetes, as well as an important indicator in evaluating the efficacy of hyperlipidemia treatment.

1. Crane FL. Biochemical functions of Coenzyme Q10. J Am Coll Nutr. 2001;20(6):591–98. PMID: 11771674

2. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271(1):195– 204. https://doi.org/10.1016/0925-4439(95)00028-3

3. Belliere J, Devun F, Cottet-Rousselle C, Batandier C, Leverve X, Fontaine E. Prerequisites for ubiquinone analogs to prevent mitochondrial permeability transition-induced cell death. J Bioenerg Biomembr. 2012;44(1):207–12. https://doi.org/10.1007/s10863-012-9434-3

4. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA. 1991;88(5):1646–50. https://doi.org/10.1073/pnas.88.5.1646

5. Martinovich GG, Cherenkevich SN. Oxidation-reduction processes in cells: Monograph. Minsk: BSU; 2008 (In Russ.)

6. Miles MV, Horn PS, Morrison JA, Tang PH, DeGrauw T, Pesce AJ. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. Clin Chim Acta. 2003;332(1–2):123–32. https://doi.org/10.1016/S0009-8981(03)00137-2

7. Niklowitz P, Menke T, Andler W, Okun JG. Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin Chim Acta. 2004;342(1–2):219–26. https://doi.org/10.1016/j.cccn.2003.12.020

8. Tomasetti M, Alleva R, Solenghi MD, Littarru GP. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors. 1999;9(2–4):231–40. https://doi.org/10.1002/biof.5520090218

9. Cherenkevich SN, Martinovich YY, Martinovich IV, Gorudko IV, Shamova EV. Redox regulation of cellular activity: concepts and mechanisms. Vestsi Natsiyanalnay akademii navuk Belarusi. Seriya biyalagichnykh navuk = Proceedings of the National Academy of Sciences of Belarus. Series of Biological Sciences. 2013;(1):92–108 (In Russ.)

10. Jones DP. Redox theory of aging. Redox Biol. 2015;5(2):71–9. https://doi.org/10.1016/j.redox.2015.03.004

11. Pradedova EV, Nimaev OD, Salyaev RK. Redox processes in biological systems. Fiziologiya rasteniy = Plant Physiology. 2017;64(6):433– 45 (In Russ.) https://doi.org/10.1134/S1021443717050107

12. Nikolaeva EA, Kharabadze MN, Zolkina IV, Kulagina TE, Vasina TN, Stavtseva SN, et al. Diagnostic value of blood coenzyme Q10 levels in children with mitochondrial diseases. Rossiyskiy vestnik perinatologii i pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2015;60(5):71–5 (In Russ.)

13. Contin M, Flor S, Martinefski M, Lucangioli S, Tripodi V. New analytical strategies applied to the determination of Coenzyme Q10 in biological matrix. Methods Mol Biol. 2015;1208:409–20. https://doi.org/10.1007/978-1-4939-1441-8_29

14. Giordano FJ. Oxygen, oxidative stress, hypoxia and heart failure. J Clin Invest. 2005; 115(3):500–8. https://doi.org/10.1172/JCI24408

15. Mortensen SA. Overview on Coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of «Q-symbio» — a multinational trial. Biofactors. 2003;18(1–4):79–89. https://doi.org/10.1172/JCI24408

16. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52(18):1435–41. https://doi.org/10.1016/j.jacc.2008.07.044

17. Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;(7):154–67. https://doi.org/10.1016/j.mito.2007.02.005

18. Yalcin A, Kilin E, Sagcan A, Kultursa H. Coenzyme Q10 concentrations in coronary artery disease. Clin Biochem. 2004;37:706–9. https://doi.org/10.1016/j.clinbiochem.2004.02.008

19. Kaya Y, Çebi A, Söylemez N, Demir H, Alp HH, Bakan E. Correlations between oxidative DNA damage, oxidative stress and coenzyme Q10 in patients with coronary artery disease. Int J Med Sci. 2012;9(8):621–26. https://doi.org/10.7150/ijms.4768

20. Lee BJ, Lin YC, Huang YC, Ko YW, Hsia S, Lin PT. The relationship between coenzyme Q10, oxidative stress, and antioxidant enzymes activities and coronary artery disease. Scientific World Journal. 2012;2012:1–8. http://doi.org/10.1100/2012/792756

21. Kontush A, Schippling S, Spranger T, Beisiegel U. Plasma ubiquinol-10 as a marker for disease: is the assay worthwhile? Biofactors. 1999;9(2–4):225–9. https://doi.org/10.1002/biof.5520090217

22. Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and heart failure: a state-of-the-art review. Circ Heart Fail. 2016;9(4):e002639. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002639

23. Drapkina OM, Chernova EM, Korneevа ON. Statins and myopathy: molecular mechanisms. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2012;8(3):469–73 (In Russ.)

24. Rumyantsev NA, Kukes VG, Kazakov RE, Rumyantsev AA, Sychev DA. Use of pharmacogenetic testing to prevent undesirable drug reactions during statin therapy. Terapevticheskiy arkhiv = Therapeutic Archive. 2017;89(1):82–7 (In Russ.) https://doi.org/10.17116/terarkh201789182-87

25. Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005;12(2):111–9. https://doi.org/10.5551/jat.12.111

26. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the Coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61(6):889–92. https://doi.org/10.1001/archneur.61.6.889

27. Larsen S, Stride N, Hey-Mogensen M, Hansen CN. Bang LE, Bundgaard H, et al. Simvastatin effects on skeletal muscle relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol. 2013;61(1):44–53. https://doi.org/10.1016/j.jacc.2012.09.036

28. Caso G, Kelly P, McNurlan MA, Lawson WE . Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–12. https://doi.org/10.1016/j.amjcard.2006.12.063

29. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–7. https://doi.org/10.1016/j.jacc.2007.02.049

30. Blescke B, Wllis R, Anthony M, Casselberry N, Datwani M, Uhley VE. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J. 2001;142(2):E2. https://doi.org/10.1067/mhj.2001.116762

31. Qu H, Meng Y, Chai H, Liang F, Zhang JY, Gao Z, Shi DZ. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. Eur J Med Res. 2018;23(1):57. https://doi.org/10.1186/s40001-018-0353-6

32. Sourris KC, Harcourt BE, Tang PH, Morley AL, Huynh K, Penfold SA, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med. 2012;52(3):716–23. https://doi.org/10.1016/j.freeradbiomed.2011.11.017

33. Ates O, Bilen H, Keles S, Alp HH, Keleş MS, Yildirim K, et al. Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy. Int J Ophthalmol. 2013;6(5):675–9. https://doi.org/10.3980/j.issn.2222-3959.2013.05.24